USD10
JBIO Shares
About Jade BiosciencesJade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
USD10
JBIO Shares
About Jade BiosciencesJade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Stats
TRADING WINDOW
Closed
OPENS AT
Oct 16 at 1:30 PM UTC
MARKET CAP
$856.66M
OPEN PRICE
$13.78
LOW (1Y)
$8.36
HIGH (1Y)
$28.00
LOW (24H)
$13.03
HIGH (24H)
$14.10
VOLUME (24H)
$980.98K
5.57%
Price history
Time | Price | Change |
|---|---|---|
Today | $13.78 | |
1 Day | $13.71 | |
1 Week | $14.32 | |
1 Month | $17.17 | |
1 Year | $9.37 |
Past performance is not a reliable indicator of future results.
Discover more
Popular cryptocurrencies
Popular prediction markets
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.